Novel |
NR3C1 |
nuclear receptor subfamily 3 group C member 1 |
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- SUMOylation of intracellular receptors
- PTK6 Expression
- Regulation of RUNX2 expression and activity
- FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
- Potential therapeutics for SARS
- Regulation of NPAS4 gene transcription
|
- Flunisolide
- Diflorasone
- Alclometasone
- Medrysone
- Amcinonide
- Fluorometholone
- Megestrol acetate
- Levonorgestrel
- Beclomethasone dipropionate
- Progesterone
- Spironolactone
- Betamethasone
- Desoximetasone
- Fluticasone propionate
- Fluocinolone acetonide
- Ulobetasol
- Triamcinolone
- Prednisone
- Flumethasone
- Fludrocortisone
- Norethisterone
- Hydrocortisone
- Mometasone
- Hydrocortamate
- Mifepristone
- Clocortolone
- Flurandrenolide
- Prednisolone
- Loteprednol etabonate
- Rimexolone
- Methylprednisolone
- Clobetasol propionate
- Fluocinonide
- Prednicarbate
- Fluoxymesterone
- Budesonide
- Dexamethasone
- Desonide
- Cortisone acetate
- Paramethasone
- Drospirenone
- Ciclesonide
- Hexane-1,6-Diol
- Aldosterone
- ORG-34517
- Difluprednate
- Ulipristal
- Fluticasone furoate
- Tixocortol
- Difluocortolone
- Gestrinone
- Deflazacort
- Onapristone
- Cortivazol
- Clobetasone
- Fluticasone
- Mometasone furoate
- Hydrocortisone aceponate
- Hydrocortisone acetate
- Hydrocortisone butyrate
- Hydrocortisone cypionate
- Hydrocortisone phosphate
- Hydrocortisone probutate
- Hydrocortisone valerate
- Segesterone acetate
- Prednisolone phosphate
- Dexamethasone acetate
- Betamethasone phosphate
- Prednisolone acetate
|
- 46,XX disorders of sex development (Disorders related to androgen excess), including: Congenital adrenal hyperplasias; Glucocorticoid resistance; Aromatase deficiency
|
Novel |
NR4A1 |
nuclear receptor subfamily 4 group A member 1 |
- AKT phosphorylates targets in the nucleus
- Nuclear Receptor transcription pathway
- Constitutive Signaling by AKT1 E17K in Cancer
|
|
|
Novel |
OGT |
O-linked N-acetylglucosamine (GlcNAc) transferase |
- HATs acetylate histones
- RIPK1-mediated regulated necrosis
- Regulation of necroptotic cell death
- UCH proteinases
- Formation of WDR5-containing histone-modifying complexes
|
|
|
Novel |
PENK |
proenkephalin |
- Peptide ligand-binding receptors
- Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
- G alpha (i) signalling events
- Post-translational protein phosphorylation
|
|
|
Novel |
PGR |
progesterone receptor |
- Nuclear signaling by ERBB4
- HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
- Nuclear Receptor transcription pathway
- SUMOylation of intracellular receptors
- Estrogen-dependent gene expression
- Developmental Lineage of Mammary Gland Luminal Epithelial Cells
- Developmental Lineage of Mammary Gland Alveolar Cells
|
- Etonogestrel
- Desogestrel
- Megestrol acetate
- Levonorgestrel
- Dydrogesterone
- Progesterone
- Spironolactone
- Lindane
- Fluticasone propionate
- Medroxyprogesterone acetate
- Mitotane
- Norethisterone
- Mometasone
- Ethynodiol diacetate
- Mifepristone
- Norgestimate
- Drospirenone
- Danazol
- Oxybenzone
- Allylestrenol
- Phthalic Acid
- Metribolone
- Tanaproget
- Telapristone acetate
- Asoprisnil
- Norelgestromin
- Gestodene
- Hydroxyprogesterone caproate
- Ulipristal
- Fluticasone furoate
- Dienogest
- Medrogestone
- Norgestrel
- Homosalate
- Enzacamene
- Gestrinone
- Darolutamide
- Demegestone
- Fluticasone
- Mometasone furoate
- Segesterone acetate
|
|
Novel |
POT1 |
protection of telomeres 1 |
- Recognition and association of DNA glycosylase with site containing an affected pyrimidine
- Cleavage of the damaged pyrimidine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Recognition and association of DNA glycosylase with site containing an affected purine
- Cleavage of the damaged purine
- Cleavage of the damaged purine
- Meiotic synapsis
- Packaging Of Telomere Ends
- Telomere Extension By Telomerase
- Polymerase switching on the C-strand of the telomere
- Processive synthesis on the C-strand of the telomere
- Telomere C-strand (Lagging Strand) Synthesis
- Telomere C-strand synthesis initiation
- Removal of the Flap Intermediate from the C-strand
- DNA Damage/Telomere Stress Induced Senescence
- Inhibition of DNA recombination at telomere
|
|
|
Novel |
PPID |
peptidylprolyl isomerase D |
|
|
|
Novel |
PROS1 |
protein S |
- Platelet degranulation
- Intrinsic Pathway of Fibrin Clot Formation
- Common Pathway of Fibrin Clot Formation
- Gamma-carboxylation of protein precursors
- Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
- Removal of aminoterminal propeptides from gamma-carboxylated proteins
- Cell surface interactions at the vascular wall
- Regulation of Complement cascade
|
- Drotrecogin alfa
- Menadione
- Sodium tetradecyl sulfate
- Kappadione
|
|
Novel |
PTP4A2 |
protein tyrosine phosphatase 4A2 |
|
|
|
Novel |
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
- Stimuli-sensing channels
- Rap1 signalling
- GP1b-IX-V activation signalling
- CD209 (DC-SIGN) signaling
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- SHOC2 M1731 mutant abolishes MRAS complex function
- Gain-of-function MRAS complexes activate RAF signaling
- IFNG signaling activates MAPKs
|
- Sorafenib
- LErafAON
- XL281
- iCo-007
- Cholecystokinin
- Regorafenib
- Dabrafenib
- Fostamatinib
|
|
Novel |
RHOBTB2 |
Rho related BTB domain containing 2 |
|
|
|
Novel |
SERPINB5 |
serpin family B member 5 |
|
- S,S-(2-Hydroxyethyl)Thiocysteine
|
|
Novel |
SGTA |
small glutamine rich tetratricopeptide repeat co-chaperone alpha |
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
|
|
|
Novel |
SHKBP1 |
SH3KBP1 binding protein 1 |
|
|
|
Novel |
SIRPA |
signal regulatory protein alpha |
- Cell surface interactions at the vascular wall
- Signal regulatory protein family interactions
- Signal regulatory protein family interactions
- Neutrophil degranulation
|
|
|
Novel |
SLC25A27 |
solute carrier family 25 member 27 |
- The fatty acid cycling model
|
|
|
Novel |
SLC34A1 |
solute carrier family 34 member 1 |
- Type II Na+/Pi cotransporters
- Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1)
- Surfactant metabolism
|
|
- Nephrolithiasis/osteoporosis, hypophosphatemic
|
Novel |
STARD13 |
StAR related lipid transfer domain containing 13 |
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
|
|
|
Novel |
STAT1 |
signal transducer and activator of transcription 1 |
- Interleukin-6 signaling
- ISG15 antiviral mechanism
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Interleukin-4 and Interleukin-13 signaling
- Interleukin-20 family signaling
- Regulation of RUNX2 expression and activity
- Interleukin-35 Signalling
- Interleukin-9 signaling
- NOTCH3 Intracellular Domain Regulates Transcription
- NOTCH3 Intracellular Domain Regulates Transcription
- Interleukin-27 signaling
- Interleukin-21 signaling
- Interferon alpha/beta signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- Inactivation of CSF3 (G-CSF) signaling
- SARS-CoV-2 activates/modulates innate and adaptive immune responses
- Signaling by ALK fusions and activated point mutants
- Growth hormone receptor signaling
- PKR-mediated signaling
- Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
- Regulation of PD-L1(CD274) transcription
|
|
- Chronic Mucocutaneous Candidiasis (CMC); Familial candidiasis (CANDF)
- IFN-gamma/IL-12 axis, including the following five diseases: IL-12 p40 subunit deficiency; IL-12 receptor (IL-12R) beta1 chain deficiency; IFN-gamma receptor (IFN gamma R) alpha chain deficiency; IFN-gamma receptor (IFN gamma R) beta chain deficiency; STAT-1 deficiency
|
Novel |
STAT3 |
signal transducer and activator of transcription 3 |
- Interleukin-6 signaling
- BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
- Interleukin-7 signaling
- Interleukin-7 signaling
- Signaling by SCF-KIT
- Signaling by cytosolic FGFR1 fusion mutants
- Downstream signal transduction
- Signalling to STAT3
- Signaling by ALK
- Senescence-Associated Secretory Phenotype (SASP)
- Signaling by Leptin
- POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
- Association of TriC/CCT with target proteins during biosynthesis
- Transcriptional regulation of pluripotent stem cells
- Interleukin-10 signaling
- Interleukin-4 and Interleukin-13 signaling
- PTK6 Activates STAT3
- PTK6 Activates STAT3
- Interleukin-20 family signaling
- MET activates STAT3
- MET activates STAT3
- Interleukin-15 signaling
- Interleukin-35 Signalling
- Interleukin-9 signaling
- Interleukin-37 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-21 signaling
- Transcriptional regulation of granulopoiesis
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
- STAT3 nuclear events downstream of ALK signaling
- Inactivation of CSF3 (G-CSF) signaling
- Cytoprotection by HMOX1
- Signaling by ALK fusions and activated point mutants
- Nuclear events stimulated by ALK signaling in cancer
- Growth hormone receptor signaling
- PKR-mediated signaling
- Regulation of PD-L1(CD274) transcription
|
|
- Oral cancer
- Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
|